Marseille, France, September 15, 2020 - ImCheck Therapeutics today announced that it has secured an additional €6 million ($7.1 million) from BB Pureos Bioventures ('Pureos') in an extension of its Series B bringing the total raised in this round to €54 million in capital (approximately $64 million).

The newly added capital underscores the broad potential of ImCheck's butyrophilin superfamily-focused pipeline and the progress the company has achieved in the ongoing EVICTION (NCT04243499) Phase I/IIa clinical trial for the company's first-in-class gamma9 delta2 (γ9δ2) T cell-activating monoclonal antibody ICT01 (anti-butyrophilin 3A). In addition to supporting EVICTION, the funding will also accelerate the development of the company's pre-clinical portfolio of antibody candidates in immuno-oncology, auto-immune and infectious disease indications.

This press release is only available in English.

Attachments

  • Original document
  • Permalink

Disclaimer

GIMV Investeringsmaatschappij Voor Vlanderen NV published this content on 15 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 September 2020 09:34:02 UTC